SynBioBeta Speaker
Ravit Netzer
Scala Biodesign
CEO & Co-founder
Dr. Ravit Netzer is the co-founder and CEO of Scala Biodesign, a computational protein design start-up that develops ScalaOS, a no-code SaaS platform enabling R&D teams to independently design enzymes, antibodies, vaccines and other complex proteins that often limit or slow development programs. Its technology allows researchers to engineer proteins to peak performance with minimal experimental effort and with no need for prior data.Scala’s proprietary approach, integrating atomistic protein design calculations, AI and evolutionary data, has been validated across diverse protein classes and applications, including enzymes for biocatalysis and DNA processing, biotherapeutics and vaccines, as evidenced by 150 + scientific publications.Under Ravit’s leadership, Scala has gained the trust of nine of the world’s top-20 pharmaceutical companies, as well as leading chemical and energy enterprises. She holds a Ph.D. in computational protein design from the Weizmann Institute of Science, where her research focused on developing novel methodologies for designing high-specificity and high-activity proteins.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Ravit
This Year
•
-
Human Health
ScalaOS: Designing proteins to their peak with minimal lab effort
Designing high-performance proteins has traditionally required extensive and time-consuming lab work. In this talk, we present ScalaOS, our multi-layered protein design platform that combines atomistic calculations, AI and evolutionary data to generate more stable and active proteins from the very first design round, dramatically reducing experimental effort while achieving peak performance. This combination of targeted design strategies with minimal testing cycles, enables scientists to independently design in their own lab faster, more efficient optimization and open the door today to a new era of protein engineering
•
-
Human Health
ScalaOS: Designing proteins to their peak with minimal lab effort
Designing high-performance proteins has traditionally required extensive and time-consuming lab work. In this talk, we present ScalaOS, our multi-layered protein design platform that combines atomistic calculations, AI and evolutionary data to generate more stable and active proteins from the very first design round, dramatically reducing experimental effort while achieving peak performance. This combination of targeted design strategies with minimal testing cycles, enables scientists to independently design in their own lab faster, more efficient optimization and open the door today to a new era of protein engineering
•
-
General
Women's Luncheon - Women of SynBio: Connect, Share, Lead
Grab a seat at the table with women from across the synthetic biology community for an engaging and welcoming luncheon. Designed for connection and conversation, this gathering brings together founders, scientists, operators, and rising talent to share experiences, spark ideas, and build lasting relationships. Expect thoughtful dialogue, new connections, and a supportive space to grow together.
•
-
General
Women's Luncheon - Women of SynBio: Connect, Share, Lead
Grab a seat at the table with women from across the synthetic biology community for an engaging and welcoming luncheon. Designed for connection and conversation, this gathering brings together founders, scientists, operators, and rising talent to share experiences, spark ideas, and build lasting relationships. Expect thoughtful dialogue, new connections, and a supportive space to grow together.
•
-
Planetary Health
Biology Without Cells: The Rise of Cell-Free Biomanufacturing
Cell-free systems are redefining what’s possible in bioproduction. By bypassing the complexity of living cells, innovators can run enzyme cascades, prototype metabolic pathways, and produce high-value molecules with unmatched speed, precision, and purity. This new class of systems—from freeze-dried reactions to continuous cell-free reactors—enables rapid iteration, on-demand production, and scalable biochemistry without the need for fermentation tanks or long development cycles.
Featuring
Amy Locks
Anzen Industries
CEO
Enzyme-stabilization expert building cell-free modular “enzyme reactors.”
Ravit Netzer
Scala Biodesign
CEO & Co-founder
Christopher Pirie
Decycle Bio
CEO
De-novo, cell-free enzyme cascades converting waste into chemicals
Neeka Mashouf
Rubi Laboratories
CEO and Co-founder
Kavya Sharman
Phase Capital
Managing Partner
•
-
Planetary Health
Biology Without Cells: The Rise of Cell-Free Biomanufacturing
Cell-free systems are redefining what’s possible in bioproduction. By bypassing the complexity of living cells, innovators can run enzyme cascades, prototype metabolic pathways, and produce high-value molecules with unmatched speed, precision, and purity. This new class of systems—from freeze-dried reactions to continuous cell-free reactors—enables rapid iteration, on-demand production, and scalable biochemistry without the need for fermentation tanks or long development cycles.
Featuring
Amy Locks
Anzen Industries
CEO
Enzyme-stabilization expert building cell-free modular “enzyme reactors.”
Ravit Netzer
Scala Biodesign
CEO & Co-founder
Christopher Pirie
Decycle Bio
CEO
De-novo, cell-free enzyme cascades converting waste into chemicals
Neeka Mashouf
Rubi Laboratories
CEO and Co-founder
Kavya Sharman
Phase Capital
Managing Partner
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
